![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sanofi’s Dupixent Snags European Approval for Treating Severe Asthma
Sanofi’s Dupixent Snags European Approval for Treating Severe Asthma
![Sanofi-logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/Sanofi-logo.gif?t=1604968321&width=430)
The European Commission gave Sanofi’s biologic Dupixent (dupilumab) the greenlight for treating severe asthma for type 2 inflammation.
The agency approved the drug as an add-on maintenance treatment for severe asthma in patients 12 years and older with type 2 inflammation. The approval is for patients who aren’t adequately treated with high dose inhaled corticosteroids plus another drug product for maintenance treatment.
The drug “offers a new treatment option for those who remain inadequately controlled with current medications, including those dependent on oral corticosteroids,” said John Reed, Sanofi’s head of research and development.
Upcoming Events
-
21Oct